Impact of the Aptar Digital Health respiratory platform on adult asthma control, medication adherence, and rescue medication usage

<bold>Background</bold> United States (US) asthma medication adherence = 22%. Medication non-adherence impacts asthma control. Digital therapeutics (DTx) may improve medication adherence and asthma control. <bold>Objectives</bold> Main objectives: determine if Aptar Digital Health (ADH) respiratory platform, a DTx, improves asthma control and controller medication adherence and decreases rescue medication use. <bold>Methods</bold> Prospective, single cohort study. 104 adult participants utilized ADH respiratory platform (HeroTracker inhaler sensor and BreatheSmart mobile app) for 3-months. HeroTracker tracked controller medication adherence and rescue medication use. Asthma Control Test (ACT) and post-study platform survey were completed using BreathSmart app. Change in controller medication adherence, ACT score, and rescue medication use between baseline, T0 and 3-months, T3 were calculated. ADH respiratory platform feedback was analysed. <bold>Results</bold> ACT score increased significantly between T0 and T3 (T0: 16.5 ± 4.7; ∆T0 to T3: + 2.8, 95% CI (2.0, 3.6), p <0.001), indicating trend in improved asthma control. Rescue medication use decreased 44% between T0 and T3 ((95% CI: 14.1, 63.5), p=.008). Controller medication adherence at T3 was 45% higher than US asthma medication adherence. 40 participants completed platform feedback survey. 82.5% reported platform was very/somewhat easy to use. 92.5% reported alerts were very/somewhat helpful. Mean platform score = 7.8 (1-10; 10=high). <bold>Conclusions</bold> ADH respiratory platform use resulted in improved asthma control and controller medication adherence and decreased rescue medication use. ADH platform feedback was positive.